Torres J F, Lyerly D M, Hill J E, Monath T P
OraVax, Inc., Cambridge, Massachusetts 02139, USA.
Infect Immun. 1995 Dec;63(12):4619-27. doi: 10.1128/iai.63.12.4619-4627.1995.
Clostridium difficile produces toxins that cause inflammation, necrosis, and fluid in the intestine and is the most important cause of nosocomial antibiotic-associated diarrhea and colitis. We evaluated C. difficile antigens as vaccines to protect against systemic and intestinal disease in a hamster model of clindamycin colitis. Formalin-inactivated culture filtrates from a highly toxigenic strain were administered by mucosal routes (intranasal, intragastric, and rectal) with cholera toxin as a mucosal adjuvant. A preparation of culture filtrate and killed whole cells was also tested rectally. The toxoid was also tested parenterally (subcutaneously and intraperitoneally) and by a combination of three intranasal immunizations followed by a combined intranasal-intraperitoneal boost. Serum antibodies against toxins A and B and whole-cell antigen were measured by enzyme-linked immunosorbent assay, neutralization of cytotoxic activity, and bacterial agglutination. The two rectal immunization regimens induced low antibody responses and protected only 20% of hamsters against death and 0% against diarrhea. The intragastric regimen induced high antibody responses but low protection, 40% against death and 0% against diarrhea. Hamsters immunized by the intranasal, intraperitoneal, and subcutaneous routes were 100% protected against death and partially protected (40, 40, and 20%, respectively) against diarrhea. Among the latter groups, intraperitoneally immunized animals had the highest serum anticytotoxic activity and the highest agglutinating antibody responses. Hamsters immunized intranasally and revaccinated intraperitoneally were 100% protected against both death and diarrhea. Protection against death and diarrhea correlated with antibody responses to all antigens tested. The results indicate that optimal protection against C. difficile disease can be achieved with combined parenteral and mucosal immunization.
艰难梭菌产生的毒素可导致肠道炎症、坏死和积液,是医院获得性抗生素相关性腹泻和结肠炎的最重要病因。我们在克林霉素诱导的结肠炎仓鼠模型中评估了艰难梭菌抗原作为疫苗预防全身性和肠道疾病的效果。以霍乱毒素作为黏膜佐剂,通过黏膜途径(鼻内、胃内和直肠)给予来自高毒力菌株的福尔马林灭活培养滤液。还经直肠测试了培养滤液和灭活全细胞的制剂。类毒素也通过非肠道途径(皮下和腹腔内)进行了测试,以及通过三次鼻内免疫然后鼻内-腹腔内联合加强免疫的方式进行了测试。通过酶联免疫吸附测定、细胞毒性活性中和及细菌凝集来检测针对毒素A和B以及全细胞抗原的血清抗体。两种直肠免疫方案诱导的抗体反应较低,仅20%的仓鼠免受死亡,0%免受腹泻。胃内免疫方案诱导的抗体反应较高,但保护作用较低,40%免受死亡,0%免受腹泻。经鼻内、腹腔内和皮下途径免疫的仓鼠100%免受死亡,部分免受腹泻(分别为40%、40%和20%)。在后者这些组中,腹腔内免疫的动物具有最高的血清抗细胞毒性活性和最高的凝集抗体反应。经鼻内免疫然后腹腔内再次免疫的仓鼠100%免受死亡和腹泻。对死亡和腹泻的保护作用与对所有测试抗原的抗体反应相关。结果表明,通过非肠道和黏膜联合免疫可实现对艰难梭菌疾病的最佳保护。